Indoor insecticide treatments emerge as powerful tool against malaria

Washington: A pair of provocative studies has thrown light into the intense ground war now underway against malaria.

In one review, researchers offer new evidence supporting indoor insecticide spraying as a way to dramatically reduce malaria deaths. In another study, scientists in Mali simultaneously affirm the effectiveness of a critical drug to treat malaria infection in the West African malaria “hot zone” amidst concerns that it may follow the path of its predecessors and succumb to resistant parasites already being detected in other parts of the world.

In the most comprehensive review to date of the malaria-fighting potential of indoor insecticide treatments, researchers at North Carolina Central University (NCCU) and Duke University found that over the last decade on average they have reduced infections in malaria endemic communities by 62 percent—despite rising insecticide resistance among mosquitoes.

But the investigators believe the more important contribution of the study is its identification of factors that appear to influence the success of indoor residual spraying (IRS).

A study led by scientists at the University of Bamako in the West African country of Mali found that that the life saving drug artemisinin continues to rapidly cure young children infected with malaria—even as it is showing signs of weakness in Southeast Asia.

The researchers raise red flags about gaps in surveillance in Africa as new evidence that drug resistance may be spreading from Thailand to Myanmar renews fears that it could soon cross to Africa and reverse decades of progress against the disease.

In an accompanying editorial, experts cite the urgent need for investment in new research and drug development.

“Both of these studies demonstrate the incremental successes and long-term challenges faced by our drive to prevent needless deaths due to malaria. Make no mistake, this is a winnable battle. We can and will ultimately eradicate malaria from its strongholds in Africa and Asia,” said James W. Kazura, MD, President of the American Society of Tropical Medicine and Hygiene.

Researchers at NCCU and Duke University conducted a “meta-analysis”— a form of research that synthesizes the results from previous studies—of 13 peer-reviewed reports published between 2000 and 2010 that considered the impact of IRS on malaria transmission in various settings, mostly in Africa. IRS involves coating the walls of homes or community buildings with insecticides in an effort to curb infections by killing malaria-carrying mosquitoes.

“Our findings show that during the last decade IRS has remained a powerful tool for fighting malaria, even though mosquitoes, particularly in Africa, are developing the ability to evade widely used insecticides,” said Dohyeong Kim, PhD, the study`s lead author and a professor in NCCU`s Department of Public Administration.

Kim said the fact that IRS can significantly reduce malaria infections is widely accepted. What`s less known, he said, are the factors that can influence the magnitude of success.

Kim and his colleagues found that IRS appears to be best at reducing malaria infections in areas experiencing a high rate of disease and where there is a threat from both Plasmodium falciparum parasites—the most deadly form of the disease—and Plasmodium vivax parasites. Also, IRS campaigns were found to be more effective if they involved several rounds of spraying. Another factor that appeared to improve IRS effectiveness was the use of the controversial insecticide DDT.

“Our (study) results show that DDT is more effective at reducing malaria prevalence than pyrethroids or other insecticides,” the authors state.

Kim said the study`s findings indicate DDT may be worth considering in locations where malaria transmission is particularly intense, but the potential health dangers of DDT would need to be weighed against its potential to reduce malaria illnesses and deaths.

Researchers at the University of Bamako in Mali sought a way to quickly detect the emergence in Africa of a malaria parasite resistant to the life-saving drug artemisinin, which several years ago emerged as the most important medicine for treating malaria—in part because parasites have defeated other first-line therapies, such as chloroquine (CQ) and sulfadoxine/pyrimethamine (SP)

Researchers using the synthetic derivative of artemisinin - called artesunate - found that it rapidly purged the deadly malaria parasite Plasmodium falciparum from infected children treated in late 2010 and 2011 in a village in Mali that has “high-intensity” seasonal malaria transmission. The median time to “parasite clearance” was 32 hours, compared to 84 hours in tests conducted in areas of Cambodia where falciparum parasites are developing resistance. Furthermore, the clearance rate in Mali was very close to what had been observed in the same village in a study conducted several years earlier.

“Our study indicates that in this region of Africa there does not appear to be any artemisinin resistance,” said Abdoulaye A. Djimde, PhD with the University of Bamako``s Malaria Research and Training Center and the senior author of the study.

The studies were published in the July 2012 issue of The American Journal of Tropical Medicine and Hygiene (AJTMH).


By continuing to use the site, you agree to the use of cookies. You can find out more by clicking this link